Editorial Team
... Read More
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookie Policy.
Written By: Editorial Team | Updated : December 13, 2014 1:21 PM IST
Skin conditions: A stem cell based gene therapy can cure skin blisters or skin tumors, a new study has found. A genetic disease called Epidermolysis Bullosa (EB) can now be successfully treated using gene therapy. In this research, skin stem cells were transplanted into the patient’s legs who was suffering from this genetic disease, and normal skin function was restored, without causing any side-effects.
London, Dec 13: According to a new study published in the journal Cancer Cell, a new family of cancer drugs designed to block several key cancer-causing proteins at once could potentially treat incurable skin cancers. The researchers said that clinical trials to test the new drugs in patients should begin as early as 2015.
Who carried out the study?
The new study, jointly led by scientists at The Institute of Cancer Research, and the Cancer Research UK Manchester Institute, showed that the new drugs - provisionally named CCT196969 and CCT241161 - stopped the growth of BRAF-driven melanomas, including those that had stopped responding to currently available BRAF-targeted drugs.
What did the study results indicate?
The existing drugs target faulty versions of a protein called BRAF which drives about half of all melanomas, but while initially very effective, the cancers almost always become resistant to treatment within a year. The new drugs - called panRAF inhibitors - could be effective in patients with melanoma who have developed resistance to BRAF inhibitors. In addition, the new drugs halted tumour growth in cancers in which BRAF-targeted drugs had never worked in the first place - which happens in around 20 per cent of cases.
What was the action mechanism?
The researchers showed that these new drugs work because they target both BRAF and the growth pathways that the cells come to rely on when they become resistant. The studies established that for both drugs, a dose of 20 mg per kg per day - which when translated to humans would be achievable by taking in pill form - caused tumours to regress without significant side-effects.
What the researchers said?
'Melanomas often respond initially to the current generation of treatments, but they inevitably acquire resistance to them, and there is a desperate need for more effective options,' said study co-leader Professor Caroline Springer, Professor of Biological Chemistry at The Institute of Cancer Research, London. 'Our new inhibitors are the first in a new family of drugs that attack cancers without allowing them the get-out clause of drug resistance, by blocking multiple cancer proteins at once.
'We are very hopeful that clinical trials from this series of new inhibitors will begin very soon - and that they will ultimately become new first or second-line options for patients who, at the moment, exhaust all the available treatments and end up with fatal disease,' Springer said.
With inputs from PTI
Image Source: Getty Images
For more articles on diseases & conditions, visit our diseases & conditions section. For daily free health tips, sign up for our newsletter.
